Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] This call is being recorded on Monday, November 10, 2025.
Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 ...
The global Fig Ingredient Market is on a strong growth trajectory, estimated at USD 714.1 million in 2025 and projected to ...
Save hours with Apple Notes. Set up smart folders, tags, and subfolders to automate organization across iPhone, iPad, and Mac ...
Learn Paste Special math, Flash Fill patterns, Go To Special filters, and the F4 shortcut to clean data fast and share Excel ...
Plus, a new program to help nonprofits learn tech tools, Pennsylvania announces an AI partnership with Penn and more Philly power moves.
Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback